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cycles of treatment in the same health state. Methods: The GRID study included a 
double-blinded phase, plus an open-label regorafenib phase for those whose disease 
progressed. The EQ-5D index was evaluated using paired-samples comparison as 
the primary analysis, and repeated measures as a sensitivity analyses. Results: 
A total of 185 subjects were included; 63% males, with an overall average age of 58 
years; 55% received study treatment as 3rd-line, the rest as 4th-line or later. 67% 
were randomized to receive regorafenib as initial double-blind therapy. Average 
utility at baseline was 0.767 units. There were no differences in baseline charac-
teristics or EQ-5D for either treatment arm, or those whose disease progressed. 
The paired-samples analysis compared progression-free EQ-5D index versus any 
first, post-progression assessment. Of those with available data (N= 77) there was a 
difference of -0.120 units (p= 0.001). In the repeated analysis, the Δ -EQ-5D between 
progression-free disease and disease progression (in double-blind phase) was -0.041 
units (p= 0.051). The mean EQ-5D index following discontinuation of open-label 
treatment due to secondary progression was much lower, with a difference of -0.231 
units (p< 0.001). Whilst adjusting for disease status and treatment, the cycle number 
did not significantly influence the EQ-5D index (p= 0.341). ConClusions: Heath-
related utility remained stable over successive treatment cycles after controlling 
for disease status and treatment type, suggesting that for subjects treated with 
regorafenib who remained progression-free, that active treatment did not lead to 
deterioration in utility. Due to the cross-over design, the repeated measures analysis 
did not contain a homogenous, group of people whose disease had progressed. Thus, 
the paired-sample analysis provides a better estimate of utility.
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objeCtives: Patient experience is increasingly recognised as an important measure 
of quality of care. A few studies have suggested that patients who report higher 
levels of satisfaction with care also have higher quality-of-life and higher psycho-
logical wellbeing, and are more likely to cooperate with treatment. In Ireland, this 
area is under-researched. The PiCTure 2 study aimed to assess the care experiences 
of men recently diagnosed with prostate cancer – the most common cancer among 
men in Ireland - and investigate associations between experiences and health-
related quality-of-life (utility) and psychological wellbeing (depression, anxiety 
and distress). Methods: Men diagnosed with invasive prostate cancer (ICD10 C61) 
5-20 months prior to study commencement were identified through the National 
Cancer Registry. The patient experience questionnaire was based on the Prostate 
Care Questionnaire (Baker et al. 2007), modified for Ireland. Utility and psychologi-
cal wellbeing were assessed using the EQ5D-5L and Depression Anxiety and Stress 
Scale (DASS-21). The questionnaire was administered by post to 2,180 men during 
January-April 2013. EQ5D-5L responses were converted to EQ5D-3L health states 
and valued with UK valuations. Results: A total of 1499 valid questionnaires were 
received (response rate= 70%). Men rated their overall care very highly; however, 
there were variations with those (i) further from diagnosis, (ii) in poorer health, 
(iii) younger, (iv) with third level education and (v) with private health insurance 
significantly more likely to report poorer care experiences. Almost half of men 
reported maximum utility scores; one-fifth had depression, one-fifth anxiety and 
one-eighth stress. Lower global experience scores were significantly associated with 
lower utility values and poorer psychological well-being (p< 0.001). ConClusions: 
While men recently diagnosed with prostate cancer report quite high overall care 
experience ratings, variations were reported and associations with lower utility and 
psychological well-being were observed. These results provide further rationale for 
initiatives to improve quality of care.
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objeCtives: The European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is one of the most com-
monly used quality of life instruments in clinical trials of anti-cancer agents. Here 
we present an algorithm for mapping between the QLQ-C30 and EQ-5D prefer-
ences in an adult population with advanced soft tissue sarcoma (aSTS) who par-
ticipated in the PALETTE trail, building upon mapping work performed in other 
tumours. Methods: Data from the PALETTE trial assessing pazopanib versus 
placebo for the treatment of aSTS (n= 369) was used, where EQ-5D was assessed at 
baseline and week 4, and the QLQ-C30 at baseline plus weeks 4, 8 and 12. Ordinary 
least squares (OLS) and generalised linear model regression using a generalised 
estimating equations (GLM/GEE) approach was employed with the EQ-5D disu-
tility value as the dependent value. A variety of model forms were tested with 
different link functions and error term distributions, as well as using two stage 
models and including factors other than QLC-C30 terms (i.e., age, sex, ECOG sta-
tus). Results: There was relatively little variability in the root mean square error 
(RMSE) and R-squared across 28 different models tested, with the RMSE ranging 
from 0.16 to 0.18 and the R-squared ranging from 0.54 to 0.63. Using GLM/GEE 
vs. OLS, adding non QLQ-C30 terms, two-stage models, and squared terms for 
QLQ-C30 scores all improved R2, albeit slightly. All the models overestimated the 
disutility for assessments with zero disutility and underestimated the disutil-
ity for assessments with large disutilities, as has commonly been reported for 
such algorithms. ConClusions: The mapping algorithms tested had reasonable 
predictive validity. These algorithms were used in cost-effectiveness evaluations 
of pazopanib in aSTS patients and may be useful for future cost-effectiveness 
evaluations of other therapies for this indication.
one year of follow up, 11.2% of TAM, and 18.4% of AI treated patients discontinued 
their treatment. In these patients with , the reasons for stopping were: progres-
sive disease including local and distant progression (68.1%), side effects (15.5%), 
patient’s choice (8.6%) and other reasons (7.8%). The multivariate hazard ratios of 
the cox regression models showed that patients younger than 50 were most likely 
to discontinue initial therapy when compared with the reference group of women 
over 70 years of age (HR: 2.30, p= 0.01). In contrast, patients treated in gynae-
cologist or oncologist practice had significantly longer persistence than patients 
who obtained their prescriptions in general hospital or academic cancer facility 
(HR: 0.47, p= 0.02). Additionally, patients with therapy initiation in gynecological 
practices had significantly longer persistence than in oncological practice (HR: 
0.68, p= 0.04). Additionally, metastases were associated with strongly increased 
risk of treatment discontinuation (HR: 3.81, p< 0.01). ConClusions: The propor-
tion of breast cancer patients with therapy discontinuation within first year after 
therapy start is high and needs to be significantly increased to improved outcome 
in clinical practice.
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objeCtives: Lung cancer has an important impact on Health related Quality of Life 
(HRQoL). LUCEOR2 is a multi-country prospective study which aimed to measure 
HRQoL and EQ-5D utility values in Non Small Cell Lung Cancer patients (NSCLC). 
Previous results presented utility values calculated on the whole LUCEOR2 popula-
tion and on the French subgroup using the UK tariff for the EQ-5D. Our aim was 
to calculate utility values with the French tariff for the application in French cost-
effectiveness studies. Methods: Data from the LUCEOR2 study that included all 
patients from participating countries which provided a meaningful sample size for 
data analysis. Patients were stratified in 7 health states defined by the response of 
treatment (progressive or stable) and the line of treatment (1st, 2nd, 3rd/4thand BSC).
EQ-5D health states were valued using the French tariff. Results: A total of 319 
patients were recruited in LUCEOR2, HRQoL were available for 258 of them (73 in 
France). Mean utilities for progression-free patients on 1st, 2nd and 3rd/4th lines were 
0.690 (n= 116; standard deviation [sd]: 0.258), 0.697(n= 46; sd: 0.221) and 0.609(n= 25; 
sd: 0.324) respectively. For patients with progressive disease, values were 0.608(n= 26; 
sd: 0.237), 0.550(n= 17; sd: 0.353) and 0.418(n= 21; sd: 0.399). Overall, patients with 
progressive disease had lower mean utility than patients with stable disease (0.530 
vs. 0.682 ; p= 0.001). Utilities calculated using the French EQ-5D tariff are lower than 
the utilities calculated using the UK tariff. ConClusions: This study presents the 
French utility values for patients with NSCLC. It demonstrates the impact of the 
disease on the HRQol. Further investigations will be made on the potential differ-
ences in scores between countries.
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objeCtives: Benefits of treatment can be measured by utility values. Health utili-
ties typically range between 0 (dead) and 1 (full health) and reflect health-related 
quality of life (HRQL) in a given health state. Societal values for health states can 
be captured using the time trade-off (TTO) methodology. Currently, no values 
exist for health states depicting stages of R/R HL and sALCL for Latin American 
countries. The aim of this study was to collect utility values from members of 
the public in Mexico and Brazil for R/R HL and sALCL health states. Methods: 
Health states were developed using recognized methods, including a litera-
ture review, patient and clinician interviews, and cognitive debriefing. States 
included stages of R/R HL and sALCL (complete response [CR], partial response 
[PR], stable disease, and progressive disease), and adverse events (AEs) including 
B-symptoms, acute/chronic graft-versus-host disease (GVHD), and grade I/II or 
grade III peripheral sensory neuropathy (PSN). Members of the public in Mexico 
(n= 100) and Brazil (n= 101) valued each health state using the TTO methodol-
ogy. Results: Participants showed a clear preference for the treatment response 
states; CR was valued as the state least likely to affect HRQL, with utility gains 
of 0.13–0.14 over stable disease. The experience of any AE was associated with a 
large decline in quality of life. The most burdensome AEs were acute GVHD and 
grade III PSN. Experiencing acute GVHD gave a disutility from stable disease of 
0.190 (for Brazil) and 0.125 (for Mexico). Only minor discrepancies existed between 
the mean utilities for the two countries, the largest being for PR (Mexico, 0.633; 
Brazil, 0.717). ConClusions: Societal valuation of health states for R/R HL and 
sALCL revealed the notable perceived benefit of a treatment response and the 
significant disutility associated with AE experience. Utility values for Mexico and 
Brazil were broadly consistent.
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objeCtives: To estimate utility values by health states for regorafenib and placebo-
treated subjects from the phase-3 GIST – Regorafenib In Progressive Disease (GRID) 
trial, and test the assumption that utility values remained constant over successive 
